COLLABORATION AND LICENSE AGREEMENTS (Details) - USD ($)			1 Months Ended			3 Months Ended		132 Months Ended
	Oct. 31, 2023	Feb. 01, 2023	Feb. 28, 2025	Apr. 30, 2023	Feb. 28, 2022	Mar. 31, 2025	Mar. 31, 2024	Mar. 31, 2025	Dec. 31, 2024	Mar. 31, 2022	Mar. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue						$ 130,000	$ 148,000	$ 223,600,000
Common stock shares issued (in shares)						71,109,514		71,109,514	71,009,866
Common stock, par value (in dollars per share)						$ 0.001		$ 0.001	$ 0.001
Unrealized gain (loss) on equity securities						$ (66,000)	4,397,000
Ligand Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt or other obligations						$ 0		$ 0
Collaborative Arrangement, Co-promotion | Takeda Pharmaceutical Company Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment under royalty and termination agreement											$ 196,000,000
Aggregate milestone payments											$ 660,000,000
Percentage of potential royalties	13.00%
License agreement milestone payments (up to)	$ 30,000,000
Ownership interest rate	87.00%
Collaborative Arrangement, Co-promotion | Takeda Pharmaceutical Company Limited | Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Related party transaction expenses recognized							0
Total revenue							0
Healx License and Option Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License and option agreement, period					1 year
Upfront payment					$ 500,000
Development and commercial milestone payments					$ 2,000,000
Granted option extension period		4 months
Percentage of development costs						50.00%
Total revenue						$ 0	$ 0
Marinus License Agreement | Marinus Pharmaceuticals, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock shares issued (in shares)										123,255
Common stock, par value (in dollars per share)										$ 0.001
Takeda Pharmaceutical Company Limited | Collaborative Arrangement, Co-promotion
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Agreement ownership share											50.00%
Marinus Pharmaceuticals, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of long-term investment			$ 70,000
Marinus Pharmaceuticals, Inc | Marinus License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Unrealized gain (loss) on equity securities						$ (1,100,000)
Graviton Bioscience Corporation | Series A Convertible Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase of preferred stock				$ 10,000,000